Genautica was formed by a group of investors, senior scientists, technologists and business professionals dedicated to identifying, funding and capturing value in the rapidly expanding field of Next Generation Sequencing (NGS), genomics and biotechnology in general.
Genautica has a strong vision for the potentials of next generation sequencing-based genomics in medicine and other related industries: better diagnostics; next-generation cancer therapies; novel bioinformatics platforms that support research and cutting-edge therapies in the health sciences; genetic expression systems for building proprietary organisms and "platform hosts"- essentially rationally designed nano-machines for the manufacturing of drugs, fuels, foods, intermediate raw materials and industrial feedstocks.
It is our expectation that the increasing speed and decreasing costs of full genomic sequencing, along with the rapidly escalating computational capabilities to handle the vast amount of genomic data, will generate many new opportunities to add value to medicine, agriculture and industry in general in the very near future. It is also our true belief that the assembly of genomic sequences, bioinformatics and industrial microbiology are the foundation of the next wave of a profound industrial revolution.
Genautica has also executed a letter of intent for an exclusive worldwide license for an unique cancer immunotherapy, which combined with NGS data analysis and neo-antigen identification technology allows a truly personalized medical treatment of cancer patients with much lower side effects than classical chemotherapy and without changing the patient's cancer treatment - just supplementing it.
Briefly, patients' own B and T cells are isolated, grown in culture and trained to recognize the tumor by providing them with a cocktail of smartly designed neo-antigens based on computer analysis of the full cancer genome. After expansion, these activated and stimulated immune cells are given back to the patient and the tumor load is monitored by a patient tumor-specific qPCR assay also developed from the individual tumor sequence footprint.